Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

INCATE: a partnership to boost the antibiotic pipeline

INCATE, the INCubator for Antibacterial Therapies in Europe, aims to boost the antibiotic pipeline by accelerating the translation of academic innovation into industrial R&D projects to tackle antimicrobial resistance. Founded in 2021 as a partnership of research institutions and pharma companies, INCATE provides advice, community and non-dilutive funding to start-up companies.
  1. Silke Alt

    1. German Center for Infection Research (DZIF), Braunschweig, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Douglas Haggstrom

    1. Innovation Office, University of Basel, Allschwil, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Helmut Kessmann

    1. Innovation Office, University of Basel, Allschwil, Switzerland; Biozentrum, University of Basel, Basel, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Florian Kloss

    1. Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Jena, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. Christian Elias Schneider

    1. Innovation Office, University of Basel, Allschwil, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  6. Timo Jäger

    1. German Center for Infection Research (DZIF), Braunschweig, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  7. Torsten Schwede

    1. Biozentrum, University of Basel, Basel, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  8. Axel Brakhage

    1. Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Jena, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  9. Christoph Dehio

    1. Biozentrum, University of Basel, Basel, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Effective antibiotics remain the cornerstone of modern medicine, and novel therapies are urgently needed to fight the threat of antimicrobial resistance (AMR). According to the recently published “Global Research on AntiMicrobial Resistance Project (GRAM)” paper, there were an estimated 4.95 million deaths associated with bacterial AMR in 2019, including 1.27 million deaths directly attributable to bacterial AMR1.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 21, 621-622 (2022)

doi: https://doi.org/10.1038/d41573-022-00138-7

Acknowledgements

The authors thank all colleagues and partners involved in INCATE (Supplementary Table 1). This work was supported by the National Center of Competence in Research AntiResist funded by the Swiss National Science Foundation (grant number 180541).

References

  1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022).

    Article  PubMed  Google Scholar 

  2. Plackett, B. Why big pharma has abandoned antibiotics. Nature 586, S50–S52 (2020).

    Article  Google Scholar 

  3. Cookson, C. UK launches world-first “subscription” model for antibiotic supply. Financial Times https://www.ft.com/content/c7cbebe4-8597-4340-8c55-56c4b423c1d1 (2022).

  4. World Bank Group: Drug-resistant infections: a threat to our economic future. https://documents.worldbank.org/en/publication/documents-reports/documentdetail/323311493396993758/final-report (2017).

  5. Cueni, T. B. Four priority actions to slow the silent pandemic of antimicrobial resistance. Health Policy Watch https://healthpolicy-watch.news/slow-the-silent-pandemic-of-antimicrobial-resistance/ (2022).

Download references

Supplementary Information

  1. Supplementary information

Competing Interests

The authors declare no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links